Nature Reviews Drug Discovery

Article	Citations
The importance of persistence in cancer drug development	2060
A new path to targeted protein degradation?	1231
A specific biomarker for insoluble tau	1036
Targeting tumour-associated bacteria	809
The improving benefit–risk balance of phase I cancer trials	699
Neutralizing Zika virus	633
Vaccine exposes tumours to immune cell attack	579
Pfizer buys Biohaven’s migraine drugs for $11.6 billion	528
Promoting tissue repair after heart attack	520
mRNA-encoded monoclonal antibody fights CHIKV	513
AI serves up target and inhibitor for lung fibrosis	461
FDA approves first all-oral sleeping sickness drug	453
Hypoimmune iPSCs escape immune detection	449
Glucose-sensitive insulin protects against hypoglycaemia	422
Tumour cells get a dendritic cell makeover	410
Targeting drug-resistant glioblastoma	405
Degrading cell-free DNA to prevent recurrent stroke	387
FDA new drug approvals in Q1 2023	383
Apolipoprotein L2 inhibitor mitigates fibrosis	380
Lipid nanoparticle ferries therapeutic mRNA to the placenta	375
Chemical engineering of CRISPR–Cas systems for therapeutic application	358
FDA approves a c-MET-targeted ADC for lung cancer	318
Anti-tau antibody stumbles in phase II Alzheimer trial	305
Evolution of innovative drug R&D in China	284
FDA approves second TTR stabilizer for cardiac amyloidosis	279

BRAF plus MEK inhibitor combo secures tumour-agnostic FDA approval	278
First-in-class IL-15 receptor agonist nabs FDA approval for bladder cancer	265
New antibiotic for urinary tract infections nabs FDA approval	262
Targeting the Hippo pathway in cancer	260
Top companies and drugs by sales in 2021	249
Small-molecule discovery through DNA-encoded libraries	239
2022 FDA approvals	236
Drugging the NLRP3 inflammasome: from signalling mechanisms to therapeutic targets	233
Increasing the potency of T cell therapies	228
mRNA vaccines for infectious diseases — advances, challenges and opportunities	228
Pushing both sides of the drug pricing aisle	215
Reflections on 10 years of the FDA’s breakthrough therapy designation	207
Blocking breast cancer metastasis	197
Rewired proteostasis in KRAS inhibitor resistance	196
Small molecule improves muscle function in myasthenia gravis	193
FDA approves anti-CD3 antibody to delay type 1 diabetes onset	180
R&D re-balancing act	176
Host-directed antiviral blocks SARS-CoV-2 entry	175
The significance of blockbusters in the pharmaceutical industry	163
Amylin takes another shot at the obesity prize	158
‘Bespoke Gene Therapy Consortium’ sets out to enable gene therapies for ultra-rare diseases	156
TCR-engineered T cells get personal	154
Author Correction: mRNA vaccines for infectious diseases: principles, delivery and clinical translation	154
A call to adapt the regulation of HLA testing for T cell receptor-based therapeutics	152
The state-of-the-art of N-of-1 therapies and the IRDiRC N-of-1 development roadmap	151
Inhibiting ASGR1 boosts cholesterol removal	146
Author Correction: Identification of neoantigens for individualized therapeutic cancer vaccines	144
Base editors hit the clinic	143
The antibody–drug conjugate landscape	140
Screening ultra-large virtual libraries	140
FDA approves second BCMA-targeted CAR-T cell therapy	130
A call to action for translational sciences in COVID-19 and future pandemics	127
FDA new drug approvals in Q2 2023	124
FDA approves first DLL3 × CD3 bispecific T-cell engager for lung cancer	123
Biomarker-guided decision making in clinical drug development for neurodegenerative disorders	119
Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape	117
Phenotypic drug discovery: recent successes, lessons learned and new directions	113
Antibody–drug conjugates come of age in oncology	113
Combating antimicrobial resistance in malaria, HIV and tuberculosis	113
The emerging role of mass spectrometry-based proteomics in drug discovery	103
Pan-coronavirus vaccine pipeline takes form	101
Gut metabolite mediates nerve repair	100
Reducing IL-2 toxicity	98
Agonist antibody lowers blood pressure	92
A novel single-agent antibiotic	91
Immunology on the brain	90
FDA approves J&J’s FcRn blocker for generalized myasthenia gravis	89
Multi-TACs target solid tumours	88
The malignant melanoma market	88
What does AlphaFold mean for drug discovery?	87

Monkeypox mRNA vaccine protects mice and macaques	86
Neglected tropical diseases go global	86
The European Innovation Network as a hub for medicines innovation in Europe	86
Anti-IL-11 antibody shows anti-ageing properties	82
GSK buys Affinivax for up to $3.3 billion, bolstering its vaccine pipeline	81
FDA approves first-in-class TRPM8 ion channel agonist for dry eye disease	78
Ribosome inhibitor combats bacterial drug resistance	76
Oral IL-23-blocking peptide racks up phase III wins in inflammatory disease	76
LRRK2-targeted Parkinson disease drug advances into phase III	76
Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies	75
Frameworks for transformational breakthroughs in RNA-based medicines	73
Author Correction: PI3K inhibitors are finally coming of age	72
Avidity in antibody effector functions and biotherapeutic drug design	70
Engineering a compact genome-editing tool	68
Engineered parasite delivers proteins to the brain	68
RNA structure guides antiviral ASO design	66
Upcoming market catalysts in Q4 2023	66
Delivering genome editing tools to primary cells	65
Covalent inhibitor engages oncogenic AKT kinase	64
A rush of CRISPR to the lungs	63
Publisher Correction: Roflumilast	63
FDA approves first PSMA-targeted radiopharmaceutical	63
Targeting protein disorder: the next hurdle in drug discovery	61
FDA approves a rare novel–novel oncology combination that pairs a first-in-class FAK inhibitor with a MEK–RAF glue inhibitor	58
Accelerating precision oncology by converging pragmatic trials and real-world evidence	57
Trends in the development of cellular and gene therapy in China	56
Broader horizons for cereblon glue degraders	56
FDA advisory committee votes for approval of first microbiome-based drug, despite data problems	56
AAV-based in vivo gene therapy for neurological disorders	52
Promoting efferocytosis heals diabetic wounds	52
Identification of neoantigens for individualized therapeutic cancer vaccines	51
MYC in cancer: from undruggable target to clinical trials	50
Investigating the origins of recent pharmaceutical innovation	49
V-ATPase inhibitor targets Ras-mutant cancers	48
Three-step cures for autoimmune diseases?	44
A bacteria-derived oral tumour vaccine	44
Designing novel macrocyclic drugs	42
Tres Cantos Open Lab: celebrating a decade of innovation in collaboration to combat endemic infectious diseases	42
RNA delivery heats up cold tumours	42
Microbial ‘dark matter’ yields new antibiotic	41
Upcoming market catalysts in Q4 2024	40
Can large, simple trials bring drug developers back to common diseases?	39
FDA approves an HDAC inhibitor for Duchenne muscular dystrophy	38
Cartilage regeneration for osteoarthritis	37
RNA chemistry and therapeutics	36
2023 FDA approvals: unprecedented volume at moderate value	36
Hinge modifier approach opens door to drugging HECT E3 ligases	35
Glue-based KRAS inhibitors make their debut cancer trial mark	35
Understanding LAG3 immune checkpoint function	34
The market for ulcerative colitis	33
FDA approves cell-sheet-based gene therapy for severe skin disease	33
Neurotensin receptor modulator safely tackles pain	31
Analysis of China-to-West pharmaceutical licensing deals in 2024	31
A new drug target for NRAS(Q61) mutant-expressing cancers	31
Immunogenicity risk assessment and mitigation for engineered antibody and protein therapeutics	30
Therapeutically harnessing extracellular vesicles	29
The case for cell-penetrating peptides	29
Novel strategies to manage CAR-T cell toxicity	29
The 60-year evolution of lipid nanoparticles for nucleic acid delivery	28
PPAR agonists provide new treatment options for inflammatory liver disease	28
Synthetic cytokine circuit targets solid tumours	28
Refining HIV pre-exposure prophylactic agents	27
miR-21 antagomir reverses COPD pathology	27
Designing closure-stabilizing integrin inhibitors	26
Targeting sigma receptor 1 in long QT syndrome	26
Transcription reprogramming to enhance CAR-T cell function	25
Publisher Correction: Evolution of the market for mRNA technology	25
Novel schizophrenia therapy filed for FDA approval	25
A faster route to antidepressant activity	25
Designing a novel synthetic receptor	25
A step closer to in vivo editing of haematopoietic stem cells	24
Anti-histamines boost immunotherapy	24
FDA approves decades-old maribavir for CMV infection	23
FDA approves 21-valent pneumococcal vaccine	23
Improving efficacy of ASO therapy in SMA	23
FDA approves PI3Kα inhibitor that does double duty as a degrader	22
Antisense and CRISPR-based drugs build cases for better hereditary angioedema treatments	22
Genome-editing medicinal products: the EMA perspective	21
PD1 × VEGF blocking bispecifics for cancer draw big backing	21
CAR T cells take to the airways	20

Unmet needs in vaccine development	20
Top product forecasts for 2025	20
Immuno-oncology clinical trials take a turn beyond PD1/PDL1 inhibitors	20
Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)	20
Sequential immunotherapy: towards cures for autoimmunity	19
Human genetics evidence supports two-thirds of the 2021 FDA-approved drugs	19
FDA approves first factor XIIa inhibitor, for hereditary angioedema	19
The aryl hydrocarbon receptor: a rehabilitated target for therapeutic immune modulation	18
Enhancing CAR-T cell efficacy through IFN ablation	18
In vivo CAR T cells move into clinical trials	18
Drugging the efferocytosis process: concepts and opportunities	17
Understanding the effects of antibiotic combinations	17
Bacteria tag tumours for CAR-T cell attack	17
FDA approval of Immunocore’s first-in-class TCR therapeutic broadens depth of the T cell engager platform	17
Targeting galectin-driven regulatory circuits in cancer and fibrosis	17
RNAi-based drug design: considerations and future directions	17
Acyl-lysine reader inhibitor blocks AML progression	16
GlaxoSmithKline buys late-stage JAK inhibitor for $1.9 billion	16
Synthesizing portimines	16
Putting a PIN in pancreatic cancer	16
Treating cannabis use disorder	16
Rediscovering hygromycin A for Lyme disease treatment	16
Epigenetic editor silences prion protein	15
Lilly’s tirzepatide secures first approval in diabetes, paving path for dual-acting hormone mimetics	15
Brain glucose mediates amphotericin B tolerance	15
Open-science drug discovery for COVID-19	15
Stalled molecular motor inhibits tumour growth	15
FDA approves first GPRC5D × CD3-targeted bispecific for multiple myeloma	14
mRNA flu shots move into trials	14
Bluebird Bio’s cut-price sale highlights challenges for gene therapy field	14
The KRAS crowd targets its next cancer mutations	14
Trustworthy AI for safe medicines	14
Neurons give metastatic cells a push	14
ASO targets DNA repair protein to combat Huntington disease	14
Thinking outside the box: non-canonical targets in multiple sclerosis	13
Lilly buys Verve and its in vivo gene editors for up to US$1.3 billion	13
Trends in the drug target landscape for autoimmune diseases	13
Bispecific antibodies in oncology	13
Building on the momentum of N-of-1 base editor therapies for rare diseases	13
opnMe.com: a digital initiative for sharing tools with the biomedical research community	13
Advanced technologies for the development of infectious disease vaccines	13
Insights into new approach methodology innovation: an EMA perspective	13
Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment	13
Antibody cocktail eliminates ebolaviruses	12
Upcoming market catalysts in Q3 2023	12
Gene editing addresses antithrombin deficiency	12
Alnylam scores big pharma support for angiotensinogen silencer	12
Understanding sphingosine-1-phosphate transport	12
A type 1 regulatory T cell-based therapy	12
Phosphatase inhibitor drives anticancer immune responses	12
A new antibiotic for A. baumannii	12
Targeting ALDH1B1 in colorectal cancer	12
Understanding immunomodulatory antibody agonism	12
The renal cell carcinoma drug market	11
Nonhormonal target for endometriosis	11
FDA releases tissue-agnostic cancer drug draft guidance	11
T cell-regulating therapies for autoimmune diseases take FDA rejection in stride	10
FDA approves first gene therapy for Duchenne muscular dystrophy, despite internal objections	10
Top product forecasts for 2022	10
Neutrophil-targeting drug seeks first approval in an inflammatory lung disease	10
FDA approves first two drugs for rare Niemann–Pick disease	10
Ramping up mitochondrial DNA replication	10
DUBTACs for targeted protein stabilization	9
Setting GPCRs free	9
Chromatin-targeted drug discovery at “a very special moment”	9
Membrane transporters in drug development and as determinants of precision medicine	9
Hooking FSH as a potential target for Alzheimer disease	9
Targeting cytokine networks in neuroinflammatory diseases	9
DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implications	9
Targeting expanded trinucleotide repeats	9
FDA approves first claudin-18.2-targeted antibody for gastric cancer	9
FDA approves first chikungunya vaccine	9
Macrophages as tools and targets in cancer therapy	9
Author Correction: The foundations of immune checkpoint blockade and the ipilimumab approval decennial	9
Two-pronged approach for macular degeneration	8
Novel drug targets in 2021	8
Hitting SEND on mRNA delivery	8
Inhibiting metallo-β-lactamases	8
Mapping cysteine ligandability	8
Targeting ephrin signalling in sepsis	8
mRNA vaccine for Lyme disease prevention	8
FDA approves second anti-amyloid antibody for Alzheimer disease	8
New route to target RAS	8
BacPROTAC to treat tuberculosis	7
Repurposing beta-blockers in breast cancer	7
Opportunities for mitochondrial disease gene therapy	7
New therapeutic candidate for Chagas disease	7
2022 FDA approval number dips: a COVID-19 hangover?	7
The potential of innovative trial design for efficiently evaluating repurposed drugs	7
Novel drug targets in 2023	7
Antibody drug conjugate combats inflammation	7
Scooping up all the drugs	7
Developing an IKZF2 glue degrader	7